Cynomolgus IGFBP4 Antibody

$322.00$847.00

Catalog #: ABCESPA1446
Product Features
Immunogen: Recombinant Cynomolgus IGFBP4 protein 
Clonality:  Mouse MAb
Cloneno: 1
Isotype: Mouse IgG1
Buffer: 0.2 μm filtered solution in PBS
Reactivity: Cynomolgus
Specificity: Cynomolgus IGFBP4No cross-reactivity in ELISA withCynomolgus IGFBP1Cynomolgus IGFBP2Cynomolgus IGFBP3Human cell lysate (293 cell line)
Application: ELISA
Recommend dilution:  ELISA: 0.5-1 μg/mL. This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Cynomolgus IGFBP4. The detection limit for Cynomolgus IGFBP4 is approximately 0.31 ng/well.
Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Background: Insulin-like growth factor binding protein 4 (IGFBP-4) is a 24-kDa protein that binds insulin-like growth factor 1 (IGF-1) and IGF-2 with high affinity and inhibits IGF action in vitro. The Insulin-like growth factor-binding protein also known as IGFBP serves as a carrier protein for Insulin-like growth factor 1. IGFBPs are clearly distinct but are sharing regions with strong homology. All members of the IGFBP family bind IGF-I and IGF-II with about equal affinity. Insulin-like growth factor (IGF) binding proteins (IGFBPs) have been shown to either inhibit or enhance the action of IGF, or act in an IGF-independent manner in the prostate. IGF-binding protein-4 (IGFBP-4) inhibits IGF-I action in vitro and is the most abundant IGFBP in the rodent arterial wall. Expression of IGFBP-4 mRNA in nontransgenic littermates was maximal in liver and kidney. IGFBP-4 is a functional antagonist of IGF-I action on SMC. There is mounting evidence that the structure of the IGFBP proteins plays a key role in the regulation of IGF bioavailability, by modulating its molecular size, capillary membrane permeability, target tissue specificity, cell membrane adherence and IGF affinity.
Size

, ,